Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Zealand Pharma A/S ADR (ZEAL)

Zealand Pharma A/S ADR (ZEAL)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,420,406
  • Shares Outstanding, K 39,765
  • Annual Sales, $ 6,200 K
  • Annual Income, $ -85,670 K
  • 60-Month Beta 1.21
  • Price/Sales 226.96
  • Price/Cash Flow N/A
  • Price/Book 5.39

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/20
See More
  • Average Estimate -0.80
  • Number of Estimates 2
  • High Estimate -0.69
  • Low Estimate -0.90
  • Prior Year -0.51
  • Growth Rate Est. (year over year) -56.86%

Price Performance

See More
Period Period Low Period High Performance
1-Month
31.62 +12.97%
on 09/11/20
39.42 -9.39%
on 09/01/20
-2.69 (-7.00%)
since 08/24/20
3-Month
31.62 +12.97%
on 09/11/20
39.50 -9.57%
on 08/19/20
-0.38 (-1.05%)
since 06/24/20
52-Week
22.00 +62.36%
on 03/16/20
44.60 -19.91%
on 02/14/20
+7.72 (+27.57%)
since 09/24/19

Most Recent Stories

More News
Zealand Announces Dosing Initiation in Type 2 Diabetes Study

Zealand's (ZEAL) partner, Boehringer Ingelheim, is developing BI 456906, a long-acting GLP-1/glucagon dual agonist, as a treatment for obesity and type 2 diabetes.

ALXN : 112.02 (-0.36%)
GERN : 1.6800 (unch)
AGTC : 4.73 (-3.07%)
ZEAL : 35.72 (+0.99%)
Why Earnings Season Could Be Great for Zealand Pharma (ZEAL)

Zealand Pharma (ZEAL) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

ZEAL : 35.72 (+0.99%)
Pharnext Announces the Appointment of David Horn Solomon as Chief Executive Officer

SA (FR0011191287 - ALPHA), an advanced clinical-stage biopharmaceutical company pioneering a new approach to developing innovative drug combinations based on big genomic data and artificial intelligence,...

AKTX : 1.6000 (-4.19%)
BNRQY : 2.0000 (+33.33%)
OXNXF : 0.8500 (unch)
SLNCF : 6.1400 (-0.97%)
SLN : 17.50 (-0.57%)
ZEAL : 35.72 (+0.99%)
Valeritas Receives Court Approval of Sale of Business to Zealand Pharma

Valeritas Holdings, Inc. (OTCPK: VLRXQ) ("Valeritas" or the "Company"), a medical technology company and maker of the V-Go® Wearable Insulin Delivery device, today announced that the U.S. Bankruptcy Court...

VLRX : 0.26 (-9.32%)
VLRXQ : 0.0200 (+33.33%)
ZEAL : 35.72 (+0.99%)
Zealand Pharma A/S to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / March 12, 2020 / Zealand Pharma A/S (NASDAQ:ZEAL) will be discussing their earnings results in their 2019 Fourth Quarter Earnings call to be held on March 12, 2020 at 4:00 PM...

ZEAL : 35.72 (+0.99%)
Rexgenero Appoints David Horn Solomon as Chairman

Rexgenero, a regenerative medicine company pioneering the development of advanced cell-based therapies to treat chronic limb-threatening ischemia (CLI), today announces that Dr. David Horn Solomon has...

SLNCF : 6.1400 (-0.97%)
SLN : 17.50 (-0.57%)
AKTX : 1.6000 (-4.19%)
ZEAL : 35.72 (+0.99%)
Valeritas Announces Agreement for Zealand Pharma to Acquire Business and Retain Employees

Valeritas Holdings, Inc. (NASDAQ: VLRX) ("Valeritas" or the "Company"), a medical technology company and maker of the V-Go® Wearable Insulin Delivery device, today announced an agreement to sell substantially...

VLRX : 0.26 (-9.32%)
ZEAL : 35.72 (+0.99%)
Zealand Initiates Second Late-Stage CHI Study on Dasiglucagon

Zealand (ZEAL) announces initiation of the second phase III study to evaluate dasiglucagon in pediatric patients with congenital hyperinsulinism.

ANIK : 33.24 (+2.09%)
ALKS : 16.53 (-1.78%)
BDSI : 3.84 (+3.50%)
ZEAL : 35.72 (+0.99%)
Bernadette Connaughton Appointed to Syneos Health Board of Directors

Syneos Health (Nasdaq:SYNH), a leading biopharmaceutical solutions organization combining a Contract Research Organization (CRO) and a Contract Commercial Organization (CCO), today announced the appointment...

ZEAL : 35.72 (+0.99%)
HALO : 25.74 (-0.54%)
SYNH : 51.29 (-1.18%)
Will Zealand Pharma Continue to Surge Higher?

As of late, it has definitely been a great time to be an investor Zealand Pharma.

ZEAL : 35.72 (+0.99%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Buy with a Weakest short term outlook on maintaining the current direction.

See More Share

Trade ZEAL with:

Business Summary

Zealand Pharma A/S is a biotechnology company. It focused on the discovery, design and development of peptide-based medicines. Zealand Pharma A/S is based in Copenhagen, Denmark.

See More

Key Turning Points

2nd Resistance Point 36.04
1st Resistance Point 35.88
Last Price 35.72
1st Support Level 35.41
2nd Support Level 35.10

See More

52-Week High 44.60
Fibonacci 61.8% 35.97
Last Price 35.72
Fibonacci 50% 33.30
Fibonacci 38.2% 30.63
52-Week Low 22.00

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar